Your search for bevacizumab returned 70 results

Tisotumab vedotin is an investigational antibody-drug conjugate targeted to tissue factor.

Study shows reductions in intraocular pressures and antiglaucoma medication use.

Phase 1 study suggests that intravitreous injection of 0.004mg may be lowest effective dose.

And, triplet and doublet drug regimens delay decline in quality of life in BRAF V600E metastatic CRC.

Addition of bevacizumab to carboplatin/pemetrexed beneficial in advanced non-small cell lung cancer

In the most recent and exhaustive reviews, bevacizumab was not associated with an increase in the risk of systemic adverse events compared with ranibizumab. In patients with age-related macular degeneration, ranibizumab may be associated with increased risk of nonocular hemorrhage compared with control treatments.

The researchers found that the hazard ratio for progression-free survival was 0.74 and 0.83 for atezolizimab plus bevacizumab versus sunitinib in PD-L1+ patients and intention-to-treat patients, respectively.

After completion of the initial bevacizumab treatment cycle, there was a significant reduction in epistaxis severity scores and RBC transfusion requirements.

Persistent diabetic macular edema more likely with bevacizumab than aflibercept or ranibizumab

However, locally assessed progression-free survival was 2.7 months longer in the combination group than in the monotherapy group.